Array BioPharma and Bristol-Myers Squibb Co. are investigating the safety, tolerability and efficacy of Array's investigational MEK inhibitor binimetinib when used with Bristol Myers Squibb's Opdivo and Opdivo + Yeroy regime.
Researchers intended to see how the treatments will affect metastatic colorectal cancer patients with microsatellite stable tumors.
Here's what you should know.
1. The companies are collaborating on a phase 1/2 study.
2. The results will determine recommended dose regimens. Researchers are hoping the treatments produce preliminary anti-tumor activity.
3. The companies want to begin the study in late 2017.
4. The companies will use the study results to propel further research.